Expertise in
12
conditions

Dr. Susan J. Steen

Neurology
Office
2919 W Swann Ave Ste 105A, 
Tampa, FL 
Expertise in
12
conditions
Office
2919 W Swann Ave Ste 105A, 
Tampa, FL 

Overview

Susan Steen is a Neurologist practicing medicine in Tampa, Florida.

Dr. Steen is highly rated in 12 conditions, according to our data. Her clinical expertise encompasses Cerebellar Degeneration, Alzheimer's Disease, Memory Loss, and Lewy Body Dementia (LBD).

She is actively involved in clinical research, co-authoring 2 peer reviewed articles and participating in 14 clinical trials.

Specialties

Neurology

Licenses

Psychiatry & Neurology in FL

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Simply Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

Office
2919 W Swann Ave Ste 105A, Tampa, FL 33609

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease
Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease
Enrollment Status: Active_not_recruiting
Publish Date: August 26, 2026
Intervention Type: Drug
Study Drug: Donanemab
Study Phase: Phase 3
Assessment of Safety, Tolerability and Efficacy of LY3002813 in Early Symptomatic Alzheimer's Disease
Assessment of Safety, Tolerability and Efficacy of LY3002813 in Early Symptomatic Alzheimer's Disease
Enrollment Status: Completed
Publish Date: March 19, 2026
Intervention Type: Drug
Study Drug: LY3002813
Study Phase: Phase 2
A Study of Donanemab Versus Placebo in Participants at Risk for Cognitive and Functional Decline of Alzheimer's Disease
A Study of Donanemab Versus Placebo in Participants at Risk for Cognitive and Functional Decline of Alzheimer's Disease
Enrollment Status: Active_not_recruiting
Publish Date: January 21, 2026
Intervention Type: Drug
Study Drug: Donanemab
Study Phase: Phase 3
A Phase 3, Open-Label, Parallel-Group, 2-Arm Study to Investigate Amyloid Plaque Clearance With Donanemab Compared With Aducanumab-avwa in Participants With Early Symptomatic Alzheimer's Disease
A Phase 3, Open-Label, Parallel-Group, 2-Arm Study to Investigate Amyloid Plaque Clearance With Donanemab Compared With Aducanumab-avwa in Participants With Early Symptomatic Alzheimer's Disease
Enrollment Status: Completed
Publish Date: November 29, 2024
Intervention Type: Drug
Study Drugs: Donanemab, Aducanumab
Study Phase: Phase 3
Development of a Biomarker Database to Investigate Aß, P-tau, and NfL Blood-Based Biomarkers and Digital Biomarkers in Older Participants Screened for Preclinical Alzheimer's Disease (AD), Prodromal AD, or Mild AD
Development of a Biomarker Database to Investigate Aß, P-tau, and NfL Blood-Based Biomarkers and Digital Biomarkers in Older Participants Screened for Preclinical Alzheimer's Disease (AD), Prodromal AD, or Mild AD
Enrollment Status: Completed
Publish Date: February 09, 2023
Intervention Type: Other
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety, Tolerability, and Efficacy of BIIB092 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease or With Mild Alzheimer's Disease
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety, Tolerability, and Efficacy of BIIB092 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease or With Mild Alzheimer's Disease
Enrollment Status: Terminated
Publish Date: November 08, 2022
Intervention Type: Drug
Study Drug: BIIB092
Study Phase: Phase 2
A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects With Early Alzheimer's Disease
A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects With Early Alzheimer's Disease
Enrollment Status: Terminated
Publish Date: September 02, 2021
Intervention Type: Drug
Study Phase: Phase 3
Effect of LY3154207 on Cognition in Mild-to-Moderate Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or Dementia With Lewy Bodies (DLB)
Effect of LY3154207 on Cognition in Mild-to-Moderate Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or Dementia With Lewy Bodies (DLB)
Enrollment Status: Completed
Publish Date: July 23, 2021
Intervention Type: Drug
Study Phase: Phase 2
Effect of LY3202626 on Alzheimer's Disease Progression as Measured by Cerebral ¹⁸F-AV-1451 Tau-PET in Mild Alzheimer's Disease Dementia
Effect of LY3202626 on Alzheimer's Disease Progression as Measured by Cerebral ¹⁸F-AV-1451 Tau-PET in Mild Alzheimer's Disease Dementia
Enrollment Status: Terminated
Publish Date: April 19, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Multicenter Screening Study With Flortaucipir F 18 in Patients With Early Symptomatic AD
A Multicenter Screening Study With Flortaucipir F 18 in Patients With Early Symptomatic AD
Enrollment Status: Completed
Publish Date: August 24, 2020
Intervention Type: Drug, Procedure
Study Phase: Phase 2
View 9 Less Clinical Trials

2 Total Publications

The 201 Trial: a placebo-controlled randomized phase 2 study of safety and tolerance of the c-Abl kinase inhibitor risvodetinib in untreated Parkinson's disease.
The 201 Trial: a placebo-controlled randomized phase 2 study of safety and tolerance of the c-Abl kinase inhibitor risvodetinib in untreated Parkinson's disease.
Journal: Nature aging
Published: June 30, 2025
Similar Doctors
Expertise in
14
conditions
Expertise in
14
conditions
Referral may be required

USF Health Parkinsons Disease & Movement Disorders

4001 E Fletcher Ave Fl 6, 
Tampa, FL 
 (10.5 miles away)
813-396-0751
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Robert Hauser is a Neurologist practicing medicine in Tampa, Florida. Dr. Hauser is highly rated in 14 conditions, according to our data. His clinical expertise encompasses Parkinson's Disease, Movement Disorders, Drug Induced Dyskinesia, and Tardive Dyskinesia. Dr. Hauser is currently accepting new patients.

Expertise in
16
conditions
Expertise in
16
conditions
Referral may be required

Univ. Medical Service Association Inc.

2 Tampa General Cir, 
Tampa, FL 
 (3.6 miles away)
813-259-0965
Languages Spoken:
English, Russian
See accepted insurances
Accepting New Patients
Offers Telehealth

Maxim Mokin is a Neurologist practicing medicine in Tampa, Florida. Dr. Mokin is highly rated in 16 conditions, according to our data. His clinical expertise encompasses Stroke, Brain Aneurysm, Apoplexy, Thrombectomy, and Stent Placement. Dr. Mokin is currently accepting new patients.

Expertise in
13
conditions
Expertise in
13
conditions
Referral may be required

Univ. Medical Service Association Inc.

2 Tampa General Cir, 
Tampa, FL 
 (3.6 miles away)
813-396-9478
Languages Spoken:
English, French, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Selim Benbadis is a Neurologist practicing medicine in Tampa, Florida. Dr. Benbadis is highly rated in 13 conditions, according to our data. His clinical expertise encompasses Seizures, Epilepsy, Generalized Tonic-Clonic Seizure, Absence Seizure, and Gastrostomy. Dr. Benbadis is currently accepting new patients.

Frequently Asked Questions about Dr. Susan J. Steen

How do I make an appointment with Dr. Susan J. Steen?

You can book an appointment with Dr. Susan J. Steen by calling their office at 813-353-9613. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Susan J. Steen a top-rated expert for Cerebellar Degeneration?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Susan J. Steen is classified as an Distinguished expert for Cerebellar Degeneration, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Susan J. Steen specialize in?

While Dr. Susan J. Steen is a Neurology, they have specific expertise in Cerebellar Degeneration, Alzheimer's Disease, and Memory Loss. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Neurology.

Does Dr. Susan J. Steen participate in research or clinical trials?

Yes. Dr. Susan J. Steen has published 2 articles and abstracts on conditions like Cerebellar Degeneration. You can view a list of Dr. Susan J. Steen's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Susan J. Steen accept my insurance?

Dr. Susan J. Steen accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 813-353-9613 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Steen's expertise for a condition
ConditionClose
    View All 9 Advanced Conditions
    View All 44 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile